MSN Laboratories Revolutionizes Autoimmune Treatment with JAK Inhibitor Launch

MSN Laboratories, a leading pharmaceutical entity in India, has made headlines by announcing the introduction of Tofacitinib and Upadacitinib, two groundbreaking JAK inhibitor molecules. This marks a significant stride in providing advanced, cost-effective treatments for autoimmune diseases such as Rheumatoid Arthritis and Crohn's Disease in India.

The company stands as a pillar in affordable medicine, having successfully launched nearly 50 first-time molecules within the Indian market. Holding the top position for Active Pharmaceutical Ingredient (API) US Drug Master File (DMF) filings, MSN Laboratories continues to pave the way in pharmaceutical innovation.

Dr. M.S.N. Reddy, the founder of MSN Group, emphasized the company's dedication to affordable healthcare, while Executive Director Mr. Bharat Reddy highlighted the public health challenge posed by autoimmune diseases. With over 25 innovative facilities, millions of patients globally have benefited from MSN's extensive product range.

(With inputs from agencies.)